Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.98
RGDX's Cash to Debt is ranked higher than
63% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.74 vs. RGDX: 3.98 )
RGDX' s 10-Year Cash to Debt Range
Min: 1.22   Max: No Debt
Current: 3.98

Equity to Asset 0.17
RGDX's Equity to Asset is ranked lower than
52% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.63 vs. RGDX: 0.17 )
RGDX' s 10-Year Equity to Asset Range
Min: -0.81   Max: 0.7
Current: 0.17

-0.81
0.7
F-Score: 2
Z-Score: -5.90
M-Score: -2.92
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -40.13
RGDX's Operating margin (%) is ranked higher than
59% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.84 vs. RGDX: -40.13 )
RGDX' s 10-Year Operating margin (%) Range
Min: -138.39   Max: 27.64
Current: -40.13

-138.39
27.64
Net-margin (%) -40.51
RGDX's Net-margin (%) is ranked higher than
59% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. RGDX: -40.51 )
RGDX' s 10-Year Net-margin (%) Range
Min: -133.14   Max: 27.86
Current: -40.51

-133.14
27.86
ROE (%) -139.28
RGDX's ROE (%) is ranked lower than
53% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.27 vs. RGDX: -139.28 )
RGDX' s 10-Year ROE (%) Range
Min: -1439.29   Max: -33.45
Current: -139.28

-1439.29
-33.45
ROA (%) -44.42
RGDX's ROA (%) is ranked higher than
53% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.84 vs. RGDX: -44.42 )
RGDX' s 10-Year ROA (%) Range
Min: -86.55   Max: 46.3
Current: -44.42

-86.55
46.3
ROC (Joel Greenblatt) (%) -218.54
RGDX's ROC (Joel Greenblatt) (%) is ranked higher than
58% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.14 vs. RGDX: -218.54 )
RGDX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -750.16   Max: 206.11
Current: -218.54

-750.16
206.11
Revenue Growth (%) -21.10
RGDX's Revenue Growth (%) is ranked higher than
56% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.80 vs. RGDX: -21.10 )
RGDX' s 10-Year Revenue Growth (%) Range
Min: -32.5   Max: 19
Current: -21.1

-32.5
19
EBITDA Growth (%) -2.90
RGDX's EBITDA Growth (%) is ranked higher than
66% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.90 vs. RGDX: -2.90 )
RGDX' s 10-Year EBITDA Growth (%) Range
Min: -30.9   Max: 23
Current: -2.9

-30.9
23
EPS Growth (%) -2.60
RGDX's EPS Growth (%) is ranked higher than
67% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.30 vs. RGDX: -2.60 )
RGDX' s 10-Year EPS Growth (%) Range
Min: -31.4   Max: -2.6
Current: -2.6

-31.4
-2.6
» RGDX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with RGDX



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 13.60
RGDX's P/B is ranked higher than
56% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.79 vs. RGDX: 13.60 )
RGDX' s 10-Year P/B Range
Min: 1.79   Max: 36.7
Current: 13.6

1.79
36.7
P/S 1.60
RGDX's P/S is ranked higher than
87% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.55 vs. RGDX: 1.60 )
RGDX' s 10-Year P/S Range
Min: 0.88   Max: 4.34
Current: 1.6

0.88
4.34
EV-to-EBIT -2.58
RGDX's EV-to-EBIT is ranked higher than
71% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. RGDX: -2.58 )
RGDX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -2.58

Current Ratio 1.87
RGDX's Current Ratio is ranked higher than
58% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.67 vs. RGDX: 1.87 )
RGDX' s 10-Year Current Ratio Range
Min: 1.14   Max: 5.28
Current: 1.87

1.14
5.28
Quick Ratio 1.87
RGDX's Quick Ratio is ranked higher than
60% of the 177 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. RGDX: 1.87 )
RGDX' s 10-Year Quick Ratio Range
Min: 1.14   Max: 5.28
Current: 1.87

1.14
5.28

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 20.50
RGDX's Price/Tangible Book is ranked higher than
60% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.20 vs. RGDX: 20.50 )
RGDX' s 10-Year Price/Tangible Book Range
Min: 1.76   Max: 31.5
Current: 20.5

1.76
31.5
Price/Median PS Value 0.80
RGDX's Price/Median PS Value is ranked higher than
90% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.41 vs. RGDX: 0.80 )
RGDX' s 10-Year Price/Median PS Value Range
Min: 0.62   Max: 1.97
Current: 0.8

0.62
1.97
Forward Rate of Return (Yacktman) -77.90
RGDX's Forward Rate of Return (Yacktman) is ranked higher than
50% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.93 vs. RGDX: -77.90 )
RGDX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 86.4   Max: 734.4
Current: -77.9

86.4
734.4

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Response Genetics, Inc. was formed as a Delaware corporation in September 1999. It is a life sciences company engaged in the research and development of innovative clinical diagnostic tests for cancer. The Company currently generates revenues mainly from sales of its ResponseDX diagnostic tests, which it launched in 2008 and by providing clinical trial testing services to pharmaceutical companies. It has developed technologies for the extraction of RNA from FFPE tissues which enable it to reliably recover RNA suitable for a variety of applications, such as gene expression research, development of diagnostics, and microarray platforms. In addition, its technologies permit gene profiling analysis of current clinical trials, most of which use the paraffin embedding technique for tissue specimen storage. The Company developed and patented extraction methodologies that allow reliable and consistent isolation of RNA and DNA from FFPE suitable for use in various types of analysis. The Company validated its methodology, which particularly addressed issues of recovery of RNA, accuracy, and precision. Further, its methodologies allow for rapid extraction of RNA with little or no DNA contamination, which makes it suitable for large-scale analysis. The Company developed ResponseDX in part by using its technology to extract genetic information from FFPE tumor specimens. Its technology provides gene expression information for each patient's tumor tissue specimen. It has developed assays for single genes comprising the ResponseDX panels for use in its CLIA lab. Assay development of these tests was done through appropriate validation procedures which determine the accuracy of each test. The Company offers ResponseDX test services nationwide. Its main sales include community based oncologists, pathologists, physician offices and hospitals. The Company is subject to various regulatory requirements designed to ensure the quality and integrity of its non-clinical testing processes. Its business is also subject to regulation under state and federal laws regarding environmental protection and hazardous substances control, such as the Federal Occupational Safety and Health Act, the Environmental Protection Act, and Toxic Substances Control Act.
» More Articles for RGDX

Headlines

Articles On GuruFocus.com
A New Beginning for Codexis? Mar 08 2013 
Response Genetics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Response Genetics Inc. Reports Operating Results (10-Q) May 14 2010 
Weekly CFO Buys Highlight: CONSTELLATION ENERGY, DPL Inc., Taylor Capital Group Inc., Physicians For Dec 19 2009 
Response Genetics Inc. (RGDX) CFO Thomas Stankovich buys 7,000 Shares Dec 14 2009 
Response Genetics Inc. Reports Operating Results (10-Q) Nov 16 2009 
Response Genetics Inc. Reports Operating Results (10-Q) Aug 21 2009 
Response Genetics, Inc. Reports Second Quarter 2009 Financial Results Driven by 70% Increase From Re Aug 13 2009 
Response Genetics, Inc. to Release Second Quarter 2009 Financial Results Aug 07 2009 
Response Genetics Inc. Reports Operating Results (10-Q) May 15 2009 

More From Other Websites
RESPONSE GENETICS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal... Jul 15 2014
RESPONSE GENETICS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders Jul 11 2014
RESPONSE GENETICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Jun 24 2014
Why Response Genetics Could Be the Business Cure for Quest Diagnostics Jun 20 2014
Response Genetics launches new test for cancer immunotherapy drug development Jun 16 2014
Response Genetics Launches New Test for Cancer Immunotherapy Drug Development Jun 16 2014
FDA-Cleared, Medicare-Reimbursed, ResponseDX: Tissue of Origin(TM) Test Added to National Institute... Jun 12 2014
RESPONSE GENETICS INC Financials May 23 2014
RESPONSE GENETICS INC Files SEC form 10-Q, Quarterly Report May 15 2014
Response Genetics to expand ResponseDX portfolio into international markets May 14 2014
Response Genetics Expands Distribution of ResponseDX(R) Product Portfolio Into International Markets May 14 2014
Response Genetics' (RGDX) CEO Thomas Bologna on Q1 2014 Results - Earnings Call Transcript May 08 2014
Response Genetics reports Q1 EPS (9c), one estimate (5c) May 08 2014
RESPONSE GENETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 08 2014
Response Genetics, Inc. Announces First Quarter 2014 Financial Results May 08 2014
Response Genetics, Inc. to Release First Quarter 2014 Financial Results and Host Conference Call on... May 01 2014
Response Genetics (RGDX) in Focus: Stock Up 18.3% Apr 04 2014
Response Genetics (RGDX) in Focus: Stock Up 18.3% Apr 04 2014
Why Response Genetics (RGDX) Stock Is Soaring Today Apr 03 2014
RESPONSE GENETICS INC Files SEC form 10-K, Annual Report Mar 31 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide